Sign in
TerminatedPhase 1/2

A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary

Key facts

Who runs it
Avenge Bio, Inc
Where
Bethesda, Boston, Houston, Pittsburgh, and Providence, United StatesSee the 5 sites
Trial code
Status
Terminated
Phase
Phase 1/2
People taking part
14 people enrolled
Started
9 Dec 2022
Ended
10 Apr 2024
Type of study
Interventional
Treatments tested
  • AVB-001 (Dose Escalation Phase)
  • AVB-001 (Dose Expansion Phase)
Record updated
24 April 2024
Why it stopped
Sponsor Decision to close study

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Have histologically confirmed, metastatic or unresectable, platinum-resistant, high-grade, serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube; Note: For the purposes of this study, platinum-resistant is defined as a patient who has received platinum-containing chemotherapy and either has platinum-refractory disease (progressed during initial platinum-based chemotherapy) or resistant disease (relapsed within 6 months of initial platinum-containing chemotherapy) or, if previously with platinum-sensitive disease, has received at least 2 lines of platinum-containing chemotherapy and progressed; Note: A pathology report confirming histology will be required for enrollment
  • Have not received more than 5 lines of prior therapy
  • May have received poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, bevacizumab (or any other antiangiogenic agent), immunotherapy, or cell therapies. (Patients with germline or somatic breast cancer gene (BRCA) mutations must have progressed or been intolerant to PARP inhibitor therapy)
  • Have an Eastern Cooperative Oncology Group performance status 0 to 1 at Screening
  • Meet the following laboratory criteria:; Absolute neutrophil count >1500/μl; Hemoglobin level ≥9.0 g/dL (transfusion allowed); Platelet count ≥100,000/μl; Creatinine clearance ≥50 mL/minute, measured using the Cockcroft-Gault formula, and serum creatinine ≤1.5 upper limit of normal (ULN); Alanine aminotransferase (ALT) ≤2.5× ULN, aspartate aminotransferase (AST) ≤2.5×ULN; and total bilirubin ≤1.5×ULN (or ≤3×ULN in cases of Gilbert's syndrome); and; International normalized ratio <1.5 and activated partial thromboplastin time (or partial thromboplastin time) within normal limits per the institution; Note: Patients on direct-acting anticoagulants or other anticoagulation medications are eligible as long as they are able to hold the drug for the laparoscopic procedure on Day 1 per institutional guidance
  • Have evidence of measurable disease on computed tomography (CT) or magnetic resonance imaging (MRI) scan as defined by RECIST v1.1; Note: Measurable disease cannot include a lesion that was biopsied. Patients must, at a minimum, have 1 measurable lesion; Note: Patients with IP disease who also have disease involving the pleural cavity or distant metastases will be eligible if they have measurable or evaluable disease in the IP cavity
  • Are willing and able to provide written informed consent or have a legally authorized representative willing and able to provide informed consent at Screening

Who cannot take part

  • Have another malignancy or have had a prior malignancy within 3 years prior to the first dose of study drug or any evidence of residual disease from a previously diagnosed malignancy, excluding adequately managed with curative-intent treatment for basal cell carcinoma, squamous cell carcinoma of the skin, cervical intraepithelial neoplasia, cervical carcinoma in situ, melanoma in situ, or ductal carcinoma in situ of the breast
  • Have a known or suspected allergy to AVB-001 or known or suspected allergy to any components of AVB-001, including alginate or seaweed
  • Have any condition that, in the opinion of the Investigator, would lead to the inability of the patient to comply with the Protocol
  • Have low-grade serous, mucinous, clear cell, or endometrioid adenocarcinoma of the ovary, primary peritoneum, or fallopian tube; carcinosarcoma; or a mixed histology tumor

Where in United States

  • National Cancer InstituteBethesda, United States
  • Massachusetts General HospitalBoston, United States
  • MD Anderson Cancer CenterHouston, United States
  • UPMC-Magee Womens HospitalPittsburgh, United States
  • Women & Infants Hospital of Rhode IslandProvidence, United States

About the trial

What the trial wants to find out

This is an open-label, First-in-Human, Phase 1/2, multicenter study to evaluate the safety and efficacy of a single dose of AVB-001. AVB-001 is an encapsulated cell product engineered to produce native human interleukin-2 (hIL-2). It is delivered intraperitoneally (IP) to patients with high grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube.

The group in the trial

  • Part 1 escalating AVB-001 between 0.6 and 3.6 ug hIL-2/kg/day; and Part 2 AVB-001 at the MTD/RP2DTreatment being tested

    Part 1: one of four ascending doses of AVB-001 planned for IP, single dose administration at each dose level cohort of the Dose Escalation Phase. Part 2: a single dose of AVB-001 at the MTD/RP2D level (determined in Part 1) to be further evaluated in the Dose Expansion Phase.

    Treatment: AVB-001 (Dose Escalation Phase) and AVB-001 (Dose Expansion Phase)

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Expansion Study of AVB-001, an Intraperitoneally Administered, Cell-Generated, Human IL-2 Immunotherapy in Patients With Platinum-Resistant, High-Grade, Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube
Record updated
24 April 2024